MedPageToday
MedPage Today) — With the DESTINY-Breast09 trial, which was presented at this year’s American Society of Clinical Oncology (ASCO) annual meeting, suggesting a shift in first-line treatment for HER2-positive metastatic breast cancer, questions…
Read More
Rethinking Maintenance Strategies in Metastatic HER2-Positive Breast Cancer
Rubi Grumbles
23:25
MedPage Today) — With the DESTINY-Breast09 trial, which was presented at this year’s American Society of Clinical Oncology (ASCO) annual meeting, suggesting a shift in first-line treatment for HER2-positive metastatic breast cancer, questions…
